RCKTのROE（自己資本利益率）は？

Rocket Pharmaceuticals IncのROEは-87.96%です。

RCKTの配当利回りは？

Rocket Pharmaceuticals Incの配当利回りは0.00%です。

RCKTの品質スコア（Quality Score）は？

当社のAIはRCKTの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

RCKTは今が買い時ですか？

当社AIのタイミングスコアは100点中29点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

RCKTはどのセクターに属しますか？

Rocket Pharmaceuticals IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

RCKT (NASDAQ) 株価分析 | ROCKET PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

RCKT AI Analysis Summary

Our AI summary for RCKT: Rocket Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -87.96%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 29/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RCKT

Rocket Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 3.41

0.30 (9.65%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-88.0%

ROE

-73.4%

ROA

0.00%

Div Yield

ROCKET PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.41 Price 0.30 (9.65%) Day Change	NEWS SCORE: N/A

RCKT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.41
PBV / Sector	1.43 / 44,219.29 GOOD
Earning Per Share	-2.10

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	6.25 M
Average 1W Daily Value	5.34 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-73.36 / 185,260.96
ROA Average (%) / Sector	-54.70 / 36,684.70
ROA Change Average (%) / Sector	16.82 / 422,221.66 GOOD
ROE (%) / Sector	-87.96 / 243,762.23
ROE Average (%) / Sector	-63.89 / 48,758.47
ROE Change Average (%) / Sector	18.86 / 424,968.10 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

登録情報

Analyze Date	2026-08-04 08:02:04
Symbol	RCKT
Name	ROCKET PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	109.19 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	339.59 / 9,645.64

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512

Phone: 609 659 8001

Website: https://www.rocketpharma.com

Employees: 202

Sector: Healthcare >> Biotechnology

Description: Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.